Evaluation of the Efficacy of MaaT013 As Salvage Therapy in Acute GVHD Patients with Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial.
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms ARES
- Sponsors MaaT Pharma
- 09 Dec 2024 Results presented in the MaaT Pharma Media Release.
- 06 Dec 2024 According to a MaaT Pharma media release, first US compassionate use case comes as MaaT Pharma completes patient recruitment for its Phase 3 ARES trial in Europe.
- 07 Nov 2024 According to a MaaT Pharma media release, updated results from its Early Access Program of MaaT013 in 154 patients with steroid-refractory (SR) or dependent (SD) gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) have been selected for poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting.